Small cell lung cancer
Drug research and approvals for small cell lung cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,540 studies of small cell lung cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 383 drug trials for it since 2013, FDA has 48 approved and 71 open orphan designations naming it, and the EU has 30 authorised medicines for it.
- Recruiting worldwide: 1,540
- Trials authorized in Canada: 383
- FDA orphan approvals: 48
- EU medicines: 30
Recruiting Now
Newest start dates first, of 1,540 recruiting on ClinicalTrials.gov ↗- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung…NCT07388524 · Phase 3 · National Cancer Institute (NCI) · starts Mar 2, 2027
- DK222 Study at HopkinsNCT07140315 · Phase 1 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · starts Jan 31, 2027
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerNCT07153055 · Phase 1 / Phase 2 · Misty Shields · starts Jan 1, 2027
- Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung…NCT07761910 · Phase 2 · Indiana University · starts Jan 1, 2027
- YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung CancerNCT07390565 · Not applicable · LI FENG · starts Dec 17, 2026
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)NCT07845786 · Phase 2 · Exelixis · starts Dec 15, 2026
- A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerNCT07603856 · Phase 2 · University of Chicago · starts Dec 12, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of…NCT07718672 · Phase 2 · Roswell Park Cancer Institute · starts Dec 1, 2026
- TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · Phase 1 · University of Pennsylvania · starts Dec 1, 2026
Trials Authorized in Canada
The 10 newest of 383; search them all in Canada trials| Nov 13, 2026 | A phase 3 randomized open-label study to evaluate the safety and efficacy of risvutatug rezetecan in combination with atezolizumab in participants with newly…RISVUTATUG REZETECAN (GSK5764227) | GSK | Pending |
| Oct 27, 2026 | Luna-2: a phase II randomized trial of lnd101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy in…LND101 | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Pending |
| Oct 22, 2026 | Rosetta lung-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants with…PUMITAMIG (BMS-986545; BNT327) | Bristol-Myers Squibb | Pending |
| Oct 15, 2026 | A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, egfr wildtype, locally…TELISOTUZUMAB ADIZUTECAN (ABBV-400) | AbbVie | Pending |
| Oct 9, 2026 | A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable nsclc (stage iii) who have…IVONESCIMAB | SUMMIT THERAPEUTICS INC. | Pending |
| Sep 11, 2026 | A phase III, randomized, open-label study of izalontamab brengitecan (bms-986507) in combination with osimertinib versus osimertinib monotherapy or osimertinib…IZALONTAMAB BRENGITECAN (BMS-986507) / TAGRISSO (OSIMERTINIB) | Bristol-Myers Squibb | Ongoing |
| Aug 27, 2026 | A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with…TRILACICLIB / CISPLATIN / CARBOPLATIN / ETOPOSIDE | Pharmacosmos | Pending |
| Aug 19, 2026 | A phase 2, multicenter, open-label, single arm study of lurbinectedin in combination with durvalumab as first-line maintenance therapy in participants with…LURBINECTEDIN / DURVALUMAB | Jazz Pharmaceuticals | Pending |
| Jun 30, 2026 | A global, multicentre, phase II platform study of datopotamab deruxtecan (dato-dxd)-based combinations in adult participants with trop2 nmr-positive non-small…DATOPOTAMAB DERUXTECAN / DURVALUMAB / CARBOPLATIN | AstraZeneca Pharmaceuticals LP | Pending |
| Jun 25, 2026 | An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…PONSEGROMAB (PF-06946860) | Pfizer | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 119| Sep 9, 2026 | Hyrnuotreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2… | Bayer HealthCare Pharmaceuticals Inc. | Approved |
| Jul 22, 2026 | Jideytrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1… | Nuvalent, Inc. | Approved |
| Nov 19, 2025 | Hyrnuotreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2… | Bayer HealthCare Pharmaceuticals Inc. | Approved |
| Oct 2, 2025 | Zepzelcain combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Oct 2, 2025 | Tecentriqin combination with lurbinectedin, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)… | Genentech, Inc. | Approved |
| Jun 11, 2025 | Ibtrozitreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) | Nuvation Bio Inc. | Approved |
| Dec 4, 2024 | Imfinzias a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed… | AstraZeneca Pharmaceuticals LP | Approved |
| Sep 25, 2024 | Tagrissotreatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not… | AstraZeneca Pharmaceuticals LP | Approved |
| May 16, 2024 | Imdelltratreatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based… | Amgen Inc. | Approved |
| Apr 18, 2024 | Alecensaadjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer… | Hoffmann-La Roche, Inc. (c/o Genentech, Inc.) | Approved |
| Feb 16, 2024 | Tagrissoin combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or… | AstraZeneca Pharmaceuticals LP | Approved |
| Nov 15, 2023 | Augtyrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) | Bristol Myers Squibb Company | Approved |
| Oct 11, 2023 | Braftoviin combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E… | Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.) | Approved |
| Sep 7, 2023 | Xalkoritreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or… | Pfizer, Inc. | Approved |
| Dec 12, 2022 | KrazatiTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an… | Bristol-Myers Squibb Company | Approved |
Medicines Authorised in the EU
Newest first; 15 of 30| May 29, 2026 | Imdylltratarlatamab · orphan | Amgen Europe B.V. | EMA ↗ |
| May 29, 2026 | Zepzelcalurbinectedin · orphan | Pharma Mar S.A. | EMA ↗ |
| Feb 3, 2025 | Hetroniflyserplulimab | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 20, 2025 | Lazcluzelazertinib | Janssen Cilag International NV | EMA ↗ |
| Jan 13, 2025 | Augtyrorepotrectinib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Jul 24, 2024 | Cejemlysugemalimab | Cstone Pharmaceuticals Ireland Limited | EMA ↗ |
| Jan 5, 2024 | Krazatiadagrasib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Sep 15, 2023 | Tevimbratislelizumab | Beone Medicines Ireland Limited | EMA ↗ |
| Jun 20, 2022 | Tabrectacapmatinib | Novartis Europharm Limited | EMA ↗ |
| Feb 16, 2022 | Tepmetkotepotinib | Merck Europe B.V. | EMA ↗ |
| Jan 6, 2022 | Lumykrassotorasib | Amgen Europe B.V. | EMA ↗ |
| Dec 9, 2021 | Rybrevantamivantamab | EMA ↗ | |
| Feb 11, 2021 | Retsevmoselpercatinib | Eli Lilly Nederland B.V. | EMA ↗ |
| May 6, 2019 | Lorviqualorlatinib | Pfizer Europe MA EEIG | EMA ↗ |
| Apr 2, 2019 | Vizimprodacomitinib | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA